P1/2, N=48, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

P2, N=105, Recruiting, Qilu Hospital of Shandong University

P3, N=100, Completed, Roche Farma S.A.

P3, N=238, Recruiting, Gruppo Oncologico del Nord-Ovest

Through modulating these tumour biological characteristics via ALDH1, bevacizumab increases the sensitivity of cervical carcinoma to cisplatin, suggesting that bevacizumab in combination with standard chemotherapy may represent a new strategy for overcoming drug resistance. Abbreviation: HPV, human papillomavirus; CSCs, cancer stem cells; ALDH1, aldehyde dehydrogenase 1; EMT, epithelial-mesenchymal transition; OD, optical density; qRT-PCR, RNA analysis by quantitative real-time polymerase chain reaction; RIPA, radioimmunoprecipitation assay; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; ECL, electrochemiluminescence; NC, negative control; HE, haematoxylin and eosin; IHC, immunohistochemistry; DAB, 3, 3'-diaminobenzidine; IF, immunofluorescence; DAPI, 4,6-diamidino-2-phenylindole; VEGFA, vascular endothelial growth factor A; ROS, oxygen species; DFS, disease-free survival; OS, overall survival; HIF, hypoxia-inducible factor; PDGFs, platelet-derived growth factors; FGFs, fibroblast growth factors; PlGF, placenta growth factor; RTKs, receptor tyrosine kinases.

P2, N=70, Recruiting, Li-kun Chen

This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and oxaliplatin)/modified CAPIRI (capecitabine and irinotecan) plus bevacizumab (anti-VEGF-A antibody) in untreated unresectable mCRC...Thus, alternating modified CAPOX/CAPIRI plus bevacizumab had promising efficacy and acceptable safety. The regimen may be a novel option for untreated unresectable mCRC.

P2, N=27, Recruiting, Northwestern University | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2026

P1/2, N=48, Not yet recruiting, University Health Network, Toronto

P3, N=822, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting

Targeted therapy, the milestone in the development of human medicine, originated in 2004 when the FDA approved the first targeted agent bevacizumab for colorectal cancer treatment...However, the efficacy of targeted therapy is extremely variable, especially with the emergence of new drugs and the innovative use of traditional targets for other tumors in recent years. Accordingly, this review provides an overview of the major signaling pathway mechanisms and recent advances in targeted therapy for gastrointestinal cancers, as well as future perspectives.

Serum IL-6 levels are thought to be involved in the suppression of tumor immunity and are useful in predicting the therapeutic effect of Atezo+Bev treatment.

P2, N=120, Active, not recruiting, University of California, Irvine | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

P=N/A, N=60, Completed, Singapore National Eye Centre | Active, not recruiting --> Completed

P2, N=24, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting

P1/2, N=380, Recruiting, Biotheus Inc. | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2025

P2, N=14, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025

P3, N=434, Not yet recruiting, Rophibio, Inc. | Initiation date: Sep 2024 --> Jan 2025

P1, N=49, Active, not recruiting, Wuhan Union Hospital, China

P2, N=32, Not yet recruiting, University of Saskatchewan | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

The randomized FIRE-4.5 (AIO KRK0116) trial compared first-line therapy with FOLFOXIRI (folinic acid, fluorouracil, oxaliplatin, and irinotecan) plus either cetuximab or bevacizumab in B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E-mutant metastatic colorectal cancer (mCRC) patients. Those patients also achieved a significantly greater disease control rate (89% vs 20%; P = 0.008). In conclusion, LB evaluating ctDNA is informative and may help to guide treatment in patients with BRAF V600E-mutated mCRC.

Five months after, the patient complained of abdominal pain, with an alpha-fetoprotein (AFP) level exceeding 9000 ng/ml, and CT images showed liver metastases and multiple lung metastases, so treatment with immunotherapy atezolizumab plus bevacizumab was started in September 2022. However, abdominal pain improved, and AFP decrease, raising suspicion of pseudoprogression. Treatment was therefore continued until radiological progression could be confirmed with a follow-up CT scan after 2 months, which revealed a complete response of the pulmonary metastasis and a partial response of the liver metastasis.

P1, N=5, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025

P1, N=11, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2025 --> Jun 2025

P2, N=73, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P1/2, N=36, Active, not recruiting, Sun Yat-sen University | Trial completion date: Oct 2024 --> Oct 2025

The side effects were mild to moderate hand-foot-syndrome, hypertension, and proteinuria. Afatinib in combination with bevacizumab are effective and safe in the management of patients with NSCLC harboring EGFR G719X, S768I, L861Q/P single or compound mutations.

P3, N=439, Not yet recruiting, BioNTech SE

P2/3, N=982, Not yet recruiting, BioNTech SE

P2, N=153, Completed, Hospices Civils de Lyon | Active, not recruiting --> Completed

We aimed to compare FOLFIRI and bevacizumab with FOLFIRI and aflibercept in terms of overall survival (OS), progression-free survival (PFS) and safety in patients with RAS-mutant metastatic colon cancer who progressed after first-line FOLFOX or XELOX and bevacizumab treatment...As a result of our study, in patients with metastatic RAS-mutant colon cancer who progressed after first-line oxaliplatin-based doublet chemotherapy and bevacizumab, better OS and PFS results were obtained in patients receiving bevacizumab with FOLFIRI compared to patients receiving aflibercept with FOLFIRI. In addition, the side effect profile was more tolerable in the bevacizumab arm.

LIPI was prognostic for PFS and OS in prospective trials in aNSCLC, regardless of the treatment regimen. LIPI poor patients derived no benefit from combination treatment. LIPI combined to PD-L1 may improve the upfront treatment selection.

Management options are limited to radiological observation, surgery, radiotherapy and, in specific cases, bevacizumab therapy...Finally, classically activated macrophages significantly colocalized with alternatively activated macrophages in static vestibular schwannoma, but this sequestration was reduced in growing vestibular schwannoma. This study provides a novel, spatial characterization of the immune landscape in growing vestibular schwannoma, whilst highlighting the need for new therapeutic targets that modulate the tumour immune micro-environment.

ARID1A mutation correlated with OCCC baseline immune activation. Stromal reconstruction and tumor metabolic reprogramming functioned as key processes of OCCC dynamic progression. VEGF inhibition remodeled OCCC stroma, restored T cell function and potentiated immunotherapy. CD36 and CD47 might be potential therapeutic targets for recurrent OCCC.

P2, N=63, Recruiting, Samsung Medical Center | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Sep 2023 --> Nov 2025

P2, N=49, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025

Notably, these effects were inhibited by the addition of bevacizumab. In conclusion, our findings illuminated the role of telocytes in promoting tumor progression, and confirmed their crucial regulatory role in the growth of tumor cells.

P4, N=30, Completed, Formycon AG

P4, N=31, Completed, Formycon AG

P2; Additionally, analysis of BRCA1 variants revealed that truncating variants in exon 11 correlated with clinical benefit when niraparib was combined with bevacizumab. Conclusively, our findings highlight the complexity of PARPi response in AOC and underscore the importance of exploring somatic variants beyond HRD status. Further investigation into exon 11 variants of BRCA1 and the potential of combination treatment is warranted.

Postoperative treatment included radiotherapy and temozolomide...The recurrence was managed with regorafenib and bevacizumab, though complications like hand-foot syndrome and radiation necrosis arose...The novel FGFR3-FASN fusion suggests potential implications for GBM recurrence and lipid metabolism. Further studies are warranted to explore FGFR3-FASN's role in GBM and its therapeutic targeting.

P=N/A, N=80, Recruiting, Medical University of Vienna | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Nov 2025